Beamtree Appoints Executive Chair for 6-Month Strategic Review to Unlock Value

Beamtree Holdings Limited (ASX: BMT) has announced significant board changes as part of its strategic review, with Emma Gray transitioning to Executive Chair for a 6-month time-limited period to oversee the review aimed at unlocking shareholder value. The announcement, made on 2 March 2026, also confirms the appointment of respected healthcare leader Martin Bowles PSM to the board.

Beamtree appoints Executive Chair to lead strategic review

Emma Gray will assume an Executive Chair role on a time-limited basis to oversee the strategic review, working closely with CEO Marek Stepniak. The arrangement is designed to allow Gray to focus on exploring strategic options whilst Stepniak concentrates on international pipeline execution and sales acceleration, particularly in key markets such as the United Kingdom and the Middle East.

The review will be supported by Non-Executive Director Stuart MacDonald and an external financial adviser. The Chair will receive remuneration equivalent to $30,000 per month for additional duties performed during the intended 6-month period. Remuneration is intended to be settled 100% via issuance of equity under the Company’s Employee Incentive Plan, subject to shareholder approval under ASX listing rule 10.14 at the 2026 Annual General Meeting.

The dual-track approach signals clear separation of responsibilities: the Executive Chair addresses strategic value unlock opportunities whilst the CEO drives commercial momentum in international markets.

What is a strategic review?

A strategic review is a formal process undertaken by a company’s board to assess options for enhancing shareholder value. For ASX-listed companies, reviews typically examine potential pathways including asset sales, strategic partnerships, capital restructures, operational changes, or potential merger and acquisition activity.

Strategic reviews are often initiated when boards believe the current market valuation does not reflect the company’s intrinsic worth. The time-limited nature of Beamtree’s review suggests the board is seeking relatively swift resolution, with outcomes likely to emerge within the 6-month timeframe specified for Gray’s Executive Chair tenure.

Board and management align interests through equity remuneration

In a move designed to strengthen alignment with shareholder returns, all Non-Executive Directors have elected to receive 100% of all relevant board fees in equity. This decision applies immediately and is subject to ASX listing rule 10.14 shareholder approval at the 2026 AGM.

Equity-based board remuneration will be calculated in accordance with the VWAP over the 6-month period following the date of the announcement.

Board Alignment Signal

The decision by all Non-Executive Directors to convert board fees entirely to equity-based remuneration represents a direct alignment of director interests with shareholder outcomes. This structure ensures board incentives are tied to share price performance during the strategic review period.

The equity remuneration structure applies to both Gray’s additional $30,000 per month Executive Chair duties and all standard Non-Executive Director fees. Pricing will be determined using VWAP methodology over the six months following 2 March 2026, creating a direct correlation between board compensation and market valuation during the strategic review period.

Experienced healthcare leader joins the board

Martin Bowles PSM has joined Beamtree’s Board of Directors, effective 2 March 2026. His appointment brings significant healthcare sector expertise and government relations experience at a time when the company is conducting its strategic review.

Martin Bowles’ key credentials include:

• National Chief Executive of Calvary Health Care for 8 years, leading one of Australia’s largest not-for-profit healthcare providers
• Former Secretary of the Federal Department of Health and Aged Care
• Recognised as a highly respected healthcare professional both in Australia and internationally

The timing of Bowles’ appointment alongside the strategic review suggests the board is strengthening governance and sector expertise ahead of potential strategic activity. His experience leading a major healthcare provider and navigating government healthcare policy positions him to provide strategic guidance during the review process.

Beamtree’s international pipeline in focus

Whilst the strategic review progresses, CEO Marek Stepniak will maintain focus on international pipeline execution and sales acceleration. The company has identified the United Kingdom and Middle East as key target markets for growth, with commercial momentum intended to continue in parallel with strategic evaluation.

The separation of responsibilities between Gray’s strategic review oversight and Stepniak’s commercial execution ensures the company can simultaneously explore value unlock opportunities whilst advancing its international expansion strategy. This dual focus maintains operational continuity and commercial development during what could otherwise be a period of internal focus on strategic alternatives.

Want the Next Healthcare Breakout in Your Inbox?

Join 20,000+ investors getting FREE breaking ASX news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive healthcare sector alerts the moment market-moving announcements drop.